Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Researchers aim to develop a functional cure for HIV using therapeutic vaccines

Researchers aim to develop a functional cure for HIV using therapeutic vaccines

EU-funded researchers are leading efforts to develop a functional cure for HIV using innovative therapeutic vaccines to halt the progression of the devastating virus, increase the availability and affordability of treatment, and improve patients’ quality of life.

The approach, which has undergone promising proof-of-concept preclinical and clinical trials in the EU-funded IHIVARNA project and is being investigated further in the HIVACAR initiative – also funded by the EU – marks a significant advance in preventive and therapeutic efforts to tackle the HIV epidemic worldwide.

‘The aim is to achieve a functional cure for HIV. No therapeutic vaccine or drug combination has achieved this goal. Therefore expectations are very high,’ says Felipe García, the coordinator of both projects at Spanish research institute IDIBAPS.

A functional cure would mean the immunodeficiency virus goes into remission, infected cells cease to replicate and the patient’s viral load is maintained at undetectable levels, preventing the onset of AIDS and other co-occurring diseases.

Although it would not eradicate HIV infection, an effective therapeutic vaccine would enable patients to live an almost normal life, less reliant on taking a daily cocktail of antiretroviral drugs in order to keep the disease under control. And while prevention measures would still be necessary, the risk of transmission to other people would be minimised, helping to halt the spread of HIV.

Vaccines on trial

In the IHIVARNA project, the researchers made important progress toward achieving that goal, using rational design techniques to develop immunogens – proteins encoded with mRNA messenger molecules capable of eliciting an immune response to HIV-1, the most widespread form of the virus.

Successful preclinical and toxicological tests enabled the team to obtain regulatory approval for a proof-of-concept candidate vaccine, leading to phase I and phase II clinical trials, including a first-in-human dose-escalating trial with HIV-infected individuals.

‘Overall, the vaccine was safe and well tolerated. It was able to induce moderate HIV-specific immune responses in the phase I clinical trial. Additional results from the phase II clinical trial are being analysed,’ García says.

In the follow-up project HIVACAR, the researchers are planning to administer therapeutic vaccines customised for each patient, alongside a potent antibody able to neutralise the binding of the virus to infected cells and a latency reversing agent, a molecule capable of unmasking the virus.

‘Using a computer-simulation-assisted drug-development technique, we have sequenced HIV-1 from four patients and have prepared four personalised vaccines that will initially be tested in animal models. Clinical trials will subsequently be conducted with a number of HIV patients in five hospitals in four European countries,’ García says. ‘The final objective is to be able to offer an alternative to current combined antiretroviral therapy for HIV-1 infected patients, although as these are proof-of-concept trials more research and further studies will be needed to confirm the results.’

Urgently seeking new strategies

A therapeutic vaccine capable of achieving a functional cure would have an enormous impact on the lives of HIV patients, who are currently reliant on taking regular doses of antiretroviral drugs for life in order to suppress the disease, often with significant side effects.

Although combined life-long antiretroviral therapy (cART) has proven highly effective in preventing disease progression and death, it has a number of public health, economic and clinical limitations. Standard cART does not fully restore health or a normal immune status in HIV-infected individuals, and patients still experience co-morbidities such as cardiovascular disease, bone disorders and cognitive impairment.

Moreover, access to treatment and the cost of the drugs is an impediment in many areas of the world, especially in developing countries which are home to a majority of the 37 million HIV patients globally. Despite improved awareness, prevention measures and more effective treatments, 2 million people still become infected with HIV worldwide each year.

‘These factors underscore the urgent need for new preventive and therapeutic strategies to be developed and tested,’ García says.

Source:

http://ec.europa.eu/research/infocentre/printversion_en.cfm?id=/research/headlines/news/article_18_11_29-1_en.html?infocentre&item=Infocentre&artid=49807

Tagged with:

About author

Related Articles